2136results about "Bacterial antigen ingredients" patented technology

The invention discloses a modified bordetella pertussis strain and an application thereof. The modified Bordetella pertussis strain is characterized in that in the Bordetella pertussis strain BAA-589, the BP2992 protein is not expressed, or the inactive BP2992 protein is expressed, the pldA protein is not expressed, or the inactive pldA protein is expressed, and the mla F protein is not expressed, or the inactive mla F protein is expressed. When the Bordetella pertussis strain is treated by combining an ultrasonic method, compared with wild Bordetella pertussis BAA-589, the Bordetella pertussis strain has a remarkable high-foaming phenotype, the OMV secretion amount is remarkably increased, and a good technical foundation is laid for developing a Bordetella pertussis OMV vaccine.

The invention discloses an immune composition containing a fatty acid modified SpyCatcher protein and a preparation method of the immune composition, and belongs to the field of biological medicines. Wherein the SpyCatcher protein (LipoSC) can be self-polymerized into nanoparticles, the SpyCatcher protein (LipoSC) is covalently linked with an antigen containing SpyTag polypeptide through an isopeptide bond, so that the immunogenicity of the loaded antigen can be improved, and a coronavirus spike protein (S protein) receptor binding domain (RBD) is taken as an example. The immune composition containing the fatty acid modified SpyCatcher protein and the coronavirus RBD antigen disclosed by the invention can induce strong RBD specific immune response, and particularly can induce mucosal immunity and humoral immunity of antigen specificity as a mucosal subunit vaccine. The invention further provides a method for finishing fatty acid modification of the SpyCatcher protein in escherichia coli and a method for preparing various immune compositions by using the fatty acid modified protein.

The invention discloses a Graisseria parasuis three-component subunit vaccine and a preparation method thereof, and belongs to the technical field of biology. The vaccine comprises three kinds of antigen proteins of the Gleisseria parasuis in an immunizing dose and a pharmaceutically acceptable adjuvant, and the amino acid sequences of the three kinds of antigen proteins are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. The invention further discloses a preparation method of the vaccine. The three-component subunit vaccine provided by the invention has cross protection force on infection of type-4 and type-5 Graisseria parasuis, has an excellent immune protection effect, and is expected to play a better role in prevention and control of infectious diseases caused by the Graisseria parasuis.

The invention provides a method for genetically modifying bordetella pertussis and application of the method. The method comprises the following steps: knocking down or knocking out a first nutrition screening gene of bordetella pertussis to generate a first auxotrophic cell; replacing the first genetic element with a second nutrition screening gene through recombination treatment to obtain a second auxotroph cell; replacing the second nutritional screening gene with the genetically modified second genetic element through recombination treatment to obtain a third nutritional deficient cell; and restoring the first nutritional screening gene to the genome of the third nutritional deficient cell through recombination treatment. In the modification process, use of antibiotics is not involved, no redundant fragments are introduced except for target modification sites, and the method has the advantages that the genetic background purity is high, and no biological safety risk exists in the modification process.

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate vaccine for preventing pneumococcal infection and respiratory syncytial virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate vaccine. According to the multivalent pneumococcal polysaccharide-protein conjugate vaccine disclosed by the invention, carrier protein is RSV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the RSV recombinant protein through a covalent bond; the RSV recombinant protein is selected from Pre-F protein, and the amino acid sequence of the RSV recombinant protein is shown as SEQ ID NO: 2 or SEQ ID NO: 3. The conjugate vaccine provided by the invention is an innovative vaccine, two common diseases, namely pneumonia and respiratory syncytial virus infection, can be simultaneously prevented by using one vaccine product, and the number of vaccination times of the vaccine is greatly reduced. According to the invention, the carrier protein in the conjugate vaccine is subjected to mutation modification, so that the carrier protein can maintain structural stability and antigen cluster function in different environments.

The discovery and application of immune checkpoint inhibitors (ICI) have significantly promoted cancer treatment. However, the response rate is still low in gastrointestinal (GI) cancers. To explore novel adjuvant treatment options, we performed fecal microbiota transplantation (FMT) of healthy donors on 10 GI cancer patients with resistance to anti-PD-(L) 1 treatment. The combination of FMT and anti-PD1 treatment was well tolerated and no serious adverse reaction was observed. Two out of 10 patients restored clinical responsiveness to anti-PD1 after FMT. Clinical benefits were shown to be associated with better colonization of co-occurred immunogenic microbes from donors, alongside activated immune status reflected by the peripheral immune cell population. Moreover, we identified microbial signatures of ICI responsiveness and validated in an independent cohort. Our study demonstrates the feasibility of FMT as a potential adjuvant therapy for ICI irresponsive GI cancer patients and laid a foundation for LBP / consortia development to enhance ICI efficacy.

The invention belongs to the technical field of biology, and discloses application of a mycoplasma hyopneumoniae Ebh GA protein in preparation of mycoplasma hyopneumoniae or a multi-combined vaccine containing the mycoplasma hyopneumoniae. The applicant screens out the Ebh GA protein with immunogenicity from the mycoplasma hyopneumoniae for the first time, the Ebh GA protein is shown in SEQ ID NO.7 and can be used as a mycoplasma hyopneumoniae subunit vaccine, and therefore the applicant screens out the protein with immunogenicity of other pathogenic bacteria at the same time and combines the protein with the protein into a quadruple subunit vaccine. The antigens of the obtained quadruple vaccine have a synergistic effect, and compared with a single dose, the quadruple vaccine can enhance the immune effect of the quadruple vaccine.

The invention relates to a fusion protein, an immunogenic composition and a recombinant degenerate vaccine for preventing and treating infection of various pathogenic streptococci, as well as a molecular architecture design, application and the like. According to the invention, three immune antigens, namely an elongation factor Tu (Tuf), a molecular chaperone DnaK and an elongation factor G (fusA), are screened, and it is proved that fusion protein molecules of the three antigens can significantly inhibit tissue lesions caused by infection of different serotypes and different types of streptococci, have good immunogenicity, play roles in immune protection and effective prevention and treatment, and have good application prospects. The bacillus subtilis has the characteristics of broad-spectrum and high-efficiency prevention of streptococcus bacterial infection, and has a wide application prospect.

The invention relates to the technical field of biology, in particular to a polyvalent pneumococcal polysaccharide-protein conjugate composition for preventing pneumococcal infection and VZV infection as well as a preparation method and application of the polyvalent pneumococcal polysaccharide-protein conjugate composition. According to the composition containing the multivalent pneumococcal polysaccharide-protein conjugate, an adopted carrier protein is a VZV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the VZV recombinant protein through a covalent bond; the VZV recombinant protein is selected from gE protein, and the amino acid sequence of the VZV recombinant protein is shown as SEQ ID NO: 3 or SEQ ID NO: 4. Aiming at the main epidemic condition of specific serotype pneumococcus in China, serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F are creatively selected, so that the composition containing the multivalent pneumococcus polysaccharide-protein conjugate, which is designed aiming at the epidemic condition of the specific serotype pneumococcus in China, is developed.

The invention provides a chemically modified tetanus toxin C fragment as well as preparation and application thereof. The method for chemically modifying the tetanus toxin C fragment comprises the following steps: 1) reacting the tetanus toxin C fragment with a reducing agent to reduce a disulfide bond in the tetanus toxin C fragment; and 2) carrying out a reaction on the reduced tetanus toxin C fragment and an alkylation reagent, and carrying out modification. The recombinant tetanus toxin C fragment prepared by the method disclosed by the invention not only meets the quality standard required by pharmacopeia, but also has the advantages of stable conformation, high yield, easiness in amplification and low cost, and has a wide application prospect in the preparation of human vaccines, veterinary vaccines and antibody drugs and the development process of in-vitro diagnostic reagents.

The invention discloses an mRNA-LNPs Brucella vaccine, an expression vector and a preparation method thereof. The mRNA-LNPs Brucella vaccine comprises at least one of mRNA of an outer membrane protein BP26 and mRNA of an outer membrane protein Omp 25. According to the present invention, the antigen sequence is optimized, the prepared mRNA Brucella vaccine can stimulate the body to produce strong immunogenicity, and compared with the Brucella vaccine prepared before the sequence optimization, the antibody titer is significantly improved. A mouse immune experiment research result shows that high-titer IgG, IgG1 and IgG2a can be generated. Th1 type reaction, Th2 type reaction or mixed Th type reaction is successfully induced.

The present invention relates to the field of veterinary vaccines, and discloses the development and application of a subunit vaccine for porcine contagious pleuropneumonia. The TbpB-C truncated protein and the AdhE whole protein selected in the antigen protein combination of the vaccine of the present invention are highly homologous in all APP serotypes, and are prepared into subunit vaccines that can provide cross protection to porcine actinobacillus pleuropneumoniae of different serotypes, and the protection rates against APP1 type and APP3 type strains are both 100%. The truncated proteins selected in the antigen protein combination of the present invention are successfully expressed in a soluble form after optimization, and are easy to express and purify in large quantities, thereby reducing production costs. The present invention lays a foundation for the development of an efficient, low-cost, broad-spectrum subunit vaccine for porcine contagious pleuropneumonia, and provides an effective technical means for the prevention and treatment of the disease.

An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin / kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and / or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

The invention discloses a streptococcus suis type 2 gene deletion strain as well as a construction method and application thereof, and belongs to the technical field of biological products. According to the invention, the B9H0105210 gene in the genome of the streptococcus suis serotype 2 SC19 is deleted in a homologous recombination manner for the first time, the hydrogen peroxide and nitric oxide stress resistance of the constructed streptococcus suis serotype 2 gene deleted strain is reduced, and the pathogenicity to mice is obviously weakened; moreover, the growth performance of the streptococcus suis type 2 gene-deleted strain is not greatly different from that of a wild strain SC19, the condition of gene recovery does not exist after continuous passage, and the streptococcus suis type 2 gene-deleted strain has an application prospect as an attenuated live vaccine, has a good immune protection effect on different genotypes of streptococcus suis such as the streptococcus suis type 2 strain SC19 and streptococcus suis type 2 P1 / 7, and has a good application prospect. And a certain cross immune protection performance is achieved.

The invention relates to the technical field of gene engineering, and particularly discloses streptococcus agalactiae WC1535 delta cps delta hylB as well as a construction method and application thereof. The streptococcus agalactiae WC1535 [delta] cps [delta] hylB is preserved in Guangdong Microbial Culture Collection Center on February 28, 2025, the preservation number is GDMCC NO.65955, and the address of the preservation unit is the 5th building, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangzhou. Compared with a traditional single-fragment deletion method, the toxicity of the deletion strain is not prone to being enhanced, and compared with a traditional injection immune vaccine, the gene deletion strain is used for preparing the tilapia oral live vaccine, the immune operation is simpler, and more labor cost is saved.

An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin / kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and / or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

The invention discloses a Bordetella pertussis strain subjected to genetic intervention as well as a preparation method and application of the Bordetella pertussis strain. Compared with the Bordetella pertussis strain BAA-589, the Bordetella pertussis strain disclosed by the invention has the advantage that the Bordetella pertussis strain has an element for reducing the expression of the BP1569 gene. The bordetella pertussis strain provided by the invention has the effect of obviously increasing the yield of OMV, and has a good application prospect in promoting the development of bordetella pertussis OMV vaccines.

The present invention provides a tumor neoantigen vaccine system specifically marking a heterologous protein, and a use thereof. The vaccine system is composed of a heterologous protein mRNA vaccine and a recombinant oncolytic virus; the heterologous protein mRNA vaccine is used to induce an organism to generate heterologous protein-specific memory T cells, and the recombinant oncolytic virus is used to promote a tumor to express microorganism-derived tumor neoantigens. When pre-immunized memory T cells detect these marked specific neoantigens, the tumor expressing the neoantigens is quickly activated and killed, the release of tumor autoantigens is promoted, dendritic cells phagocytize antigens to further initiate an anti-tumor response, and a systemic anti-tumor immune effect is activated by means of antigenic epitope spreading.

The invention relates to the technical field of biology, in particular to a brucella attenuated live vaccine strain M5 delta lysR21 as well as an attenuating method and application thereof, the M5 delta lysR21 is obtained by deleting a lysR21 gene from a brucella melitensis M5 strain, the brucella attenuated live vaccine strain MS delta lysR21 is preserved in China General Microbiological Culture Collection Center, and the preservation number is CGMCC NO. The strain is preserved in CGMCC (China General Microbiological Culture Collection Center) at No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing on November 21, 2024, and has the preservation number of CGMCC NO.32791. The invention finds that the lysR21 gene is related to the virulence of the Brucella, the deletion of the lysR21 gene can weaken the virulence of the Brucella, can significantly reduce the survival ability of the Brucella in cells and in mice, shows higher immunoprotectiveness than a vaccine strain, can be used as a candidate attenuated live vaccine strain for preventing animal brucellosis, and has potential application value.

The present invention relates to polypeptide and peptide vaccine compositions and methods that reduce methane and / or hydrogen production in animals. The present invention also relates to the treatment of diseases that are associated with methanogens.

The invention provides an inactivated bacterial preparation as well as a preparation method and application thereof. According to the method, the manganese-containing oxidizing agent and bacterial pathogens are incubated, and the purpose of inactivating bacteria is achieved within a short time by utilizing the strong oxidizing property of the manganese-containing oxidizing agent; and slowly dripping a polyphenol monomeric compound solution into the system, self-polymerizing on the surface of the bacteria under the action of the manganese-containing oxidizing agent, reducing the manganese-containing oxidizing agent to form a manganese adjuvant, attaching the manganese adjuvant to the surface of the bacteria, and simultaneously loading the manganese adjuvant on the surface of the bacteria. The method is suitable for various bacteria and polyphenol monomers. The prepared inactivated bacterial preparation can effectively induce humoral immunity and cellular immunity response of antigen specificity and effectively protect bacterial infection, and has wide application prospects in antibacterial vaccines and vaccine adjuvants.

The present invention relates to a recombinant Mycobacterium bovis BCG strain comprising a plasmid having a short guide RNA (sgRNA) target sequence for knocking out the Mb3739 gene. Also provided are vaccine compositions for eliciting an immune response against Mycobacterium tuberculosis comprising a recombinant Mycobacterium bovis BCG strain engineered to activate the NOD-1 pathway. The recombinant Mycobacterium bovis BCG strain or vaccine composition can be used in a method against an immune response initiated by Mycobacterium tuberculosis. The invention also relates to a method for obtaining the recombinant bovine mycobacterium BCG strain.

Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be directed to use in the eye of a subject. In some embodiments, the immunogenic compositions disclosed herein enhance non-specific immune responses in the eye of a subject to treat or reduce the risk of onset of an eye condition. In other embodiments, compositions disclosed herein can be used to treat eye infections due to a microorganism, tumors of the eye, as well as, chronic wounds or infections of the eye. In some embodiments, immunogenic ocular formulations disclosed herein include combinations of agents for prolonged exposure to the eye for improved outcomes.

To provide lipid-therapeutic nucleic acid compositions that encapsulate nucleic acids with high efficiency, have high drug:lipid ratios, protect the encapsulated nucleic acids from degradation and clearance in serum, are suitable for systemic delivery, and enable intracellular delivery of the encapsulated nucleic acids.SOLUTION: The invention provides lipids, or salts or isomers thereof. In the formula: R1 and R2 are each independently for each occurrence C10-C20 alkenyl; R3 is ω-aminoalkyl, ω-(substituted)aminoalkyl, or ω-thiophosphoalkyl; E is C(O)O; provided that if R3 is 2-(dimethylamino)ethyl then neither R1 nor R2 is linoleyl.SELECTED DRAWING: None

The invention provides a microneedle delivery system comprising a plurality of microneedles, a preparation method and application, and relates to the technical field of biology. The microneedle delivery system comprises a microneedle array, the microneedle array comprises at least two microneedle groups, and each microneedle group comprises a plurality of microneedles; the microneedles in the at least two microneedle groups are loaded with a medicine containing an antigen component, and the antigen component contains at least one antigen; the microneedles in different microneedle groups contain antigen components with different compositions, and the microneedles in the same microneedle group contain antigen components with the same composition. The microneedle delivery system relieves the technical problem that various vaccines are difficult to be combined for use.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

Provided herein are nucleic acid vaccine constructs comprising synthetic polynucleotides encoding a Mycobacterium tuberculosis (Mtb) RelA-SpoT homolog (RSH) protein, RelMtb, or a functional portion, fragment, or variant thereof, conjugated to a macrophage inflammatory protein-3 alpha (MIP-3α) or other chemokine that binds to a chemokine receptor 6 (CCR6), or a functional portion, fragment, or variant thereof, or to an antibody, or antigen binding portion thereof, that binds to a CCR6. Methods for making the vaccine constructs and their use in prophylaxis and treatment of Mtb infections are also provided.

The process comprises providing a recombinant vaccine construct, wherein said construct comprises genetically modified Lactobacillus plantarum NC8 as a live vector; modifying the genetic structure of said Lactobacillus plantarum NC8 to express conserved Salmonella antigens, including PagN, SopE2, and FliC, anchored by a ptrk 892 backbone with a constitutive promoter, phosphoglycerate mutase (PGM); incorporating Signal Lp_2145 and cAM12 Anchor sequences into said genetic construct to enhance surface expression of recombinant proteins on Lactobacillus plantarum NC8; administering said recombinant vaccine orally to poultry, leveraging the probiotic properties of Lactobacillus plantarum NC8 for effective colonization of the poultry gastrointestinal tract; inducing a prolonged and intensified immune response by ensuring sustained high-level expression of target antigens through the utilization of the robust constitutive promoter, phosphoglycerate mutase (PGM); and optimizing immunogenicity through the surface expression of recombinant proteins on Lactobacillus plantarum NC8, fostering a robust and precisely targeted immune response.

The invention discloses construction and application of a streptococcus suis serotype 2 cps2C gene knockout mutant strain. The invention relates to a streptococcus suis serotype 2 cps2C gene knockout mutant strain 05ZYH33 delta cps2C. A coding gene, from the 31st site to the 1000th site, of the cps2C gene in the strain 05ZYH33 is replaced by a spectinomycin resistance gene cassette SpcR. The mutant strain 05ZYH33 delta cps2C is applied to preparation of a streptococcus suis type 2 attenuated vaccine and a subunit vaccine. The capsule of the mutant strain 05ZYH33 delta cps2C is obviously reduced; in-vitro experiments show that the macrophage phagocytosis resistance of the mutant strain 05ZYH33 delta cps2C is reduced, and animal toxicity test results show that the toxicity of the mutant strain is obviously reduced. The mutant strain provides an important clue for screening of protective antigens of multivalent subunit vaccines, and can be applied to development of S.suis attenuated vaccines and multivalent subunit vaccines.